MGX

0.56507.95%
ML

Mark Leonard

Senior Vice Pres­i­dent of Tech­ni­cal Devel­op­ment & Oper­a­tions

Mr. Mark Leonard is Senior Vice President of Technical Development & Operations of Metagenomi Therapeutics, Inc. (formerly known as Metagenomi, Inc.) from November 2025. Prior to joining Metagenomi, he served as Vice President, Process and Product Development at Allogene Therapeutics, where he built the team from the ground up and had broad accountability for development and manufacturing support/MSAT activities in the delivery of Allogene’s novel allogeneic CAR T cell therapy products — from cell starting material to CAR T cell drug product, including gene-editing mRNAs and lentiviral vector drug substance and their “companion” lymphodepletion antibody. Prior to Allogene, he was Executive Director of Cell and Gene Therapy Technical Development in the Biotherapeutics Pharmaceutical Sciences organization at Pfizer and held positions of increasing responsibility at Wyeth/Genetics Institute. He holds a Ph.D. in Molecular Biology from the University of London, King’s College, Dept. of Biophysics and was a Leukemia Society of America Postdoctoral Fellow at Northwestern University, Evanston, IL.

Positions